Applied and molecular immunology, cancer immunobiology, vaccines – immunology and technology
Highton AJ, Korjarunchitt, Girardin A, Hook S, Kemp RA. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunol. Cell Biol. 2015 epub ahead of print
Highton AJ and Kemp RA. Immunological Background. In Subunit Vaccines, Springer 2015.
Neumann S, Burket K, Kemp R, Rades T, Dunbar PR, Hook S. Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunol. Cell Biol. 2014 92(6):535-42
Kemp RA, Dunn E, Schultz M. Immunomodulators in Inflammatory Bowel Disease: an emerging role for biologic agents. BioDrugs 2013 27(6):585-90
Girardin A, McCall J, Black MA, Edwards F, Phillips V, Taylor ES, Reeve AE, Kemp RA. Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. Int J Cancer 2013 132(8):1842-50.
Gordon S, Young K, Wilson R, Rizwan S, Kemp R, Rades T, Hook S. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems. J Liposome Res 2012 22(3):193-204
Kemp RA, Black MA, McCall J, Yoon HS, Phillips V, Anjomshoaa A, Reeve AE. T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer. J Exp Clin Cancer Res 2011 30(1):78
Ting YT, Coates PT, Marti HP, Dunn AC, Parker RM, Pickering JW, Jack RW, Kemp RA, Walker RJ, McLellan AD. Urinary soluble HLA-DR is a ?potential biomarker for acute renal transplant rejection. Transplantation 2010 89(9):1071.
Kemp RA, Pearson CF, Cornish GH, Seddon BP. Evidence of STAT5 dependent and independent routes to CD8 memory formation and a preferential role for IL-7 over IL-15 in STAT5 activation. Imm. Cell. Biol. 2010 88(2):213.
Bouwer AL, Netter P, Kemp RA, McLellan AD. A defined serum-free medium useful for monitoring anti-melanoma responses induced by dendritic cell immunotherapy. J. Immunol. Methods. 2010. 352(1-2):178.
Kemp RA, Yoon HS, Anjomshoaa A, Reeve AE. Using T cell responses in the lymph node to predict patient outcome in colorectal cancer. J. Immunol. 2009. 182:40.16
Kemp RA, Backstrom BT, Ronchese F. The phenotype of Type 1 and Type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity. Immunol. 2005 Jul; 115(3) 315-24.
Jelley-Gibbs DM, Dibble JP, Filipson S, Haynes L, Kemp RA, Swain SL. Repeated stimulation of CD4 effector T cells can limit their protective function. J Exp Med. 2005 Apr; 210(7):1101-12.
Powell TJ, Brown DM, Hollenbaugh JA, Charbonneau T, Kemp RA, Swain SL, Dutton RW. CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency. Clin Immunol. 2004 Oct;113(1):89-100.
Kemp RA, Powell TJ, Dwyer DW, Dutton RW. Cutting edge: regulation of CD8+ T cell effector population size. J Immunol. 2004 Sep 1;173(5):2923-7.
Begg, D, Kemp R, Griffin JFT. Normal levels of immunocompetence in possums (Trichosurus vulpecula) exposed to different laboratory housing conditions post capture. Immunol Cell Biol. 2004 Jun;82(3):253-6.
Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol. 2001 Dec 1;167(11):6497-502.
*Chtanova T, *Kemp RA, Sutherland AP, Ronchese F, Mackay CR. Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) type 1 and type 2 T cells. J Immunol. 2001 Sep 15;167(6):3057-63. * contributed equally
Ritchie DS, Hermans IF, Lumsden JM, Scanga CB, Roberts JM, Yang J, Kemp RA, Ronchese F. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Methods. 2000 Dec 1;246(1-2):109-17